PURPOSE OF REVIEW: To identify the different indications for the treatment of neurologic disorders with the potassium channel blockers 4-aminopyridine (4-AP) and 3,4-diaminopyridine (3,4-DAP). RECENT FINDINGS: 4-AP is an effective symptomatic treatment for downbeat nystagmus (DBN), episodic ataxia type 2 (EA2) (5-10 mg TID), and impaired gait in multiple sclerosis (MS) (10 mg BID). 3,4-DAP (5 mg/d-20 mg TID) improves symptoms in Lambert-Eaton myasthenic syndrome (LEMS) (randomized placebo-controlled trials for all 4 entities). 4-AP may also be effective in cerebellar gait ataxia of different etiologies (2 case series), upbeat nystagmus, and limb ataxia in MS (single cases). In the recommended dosages, they are well tolerated. The assumed mode of action is a blockade of mainly Kv1.5: in DBN, this increases the excitability of Purkinje cells (PC), and in EA2, restores the precision of resting discharge of PC. In MS, 4-AP improves the conduction of action potentials in demyelinated axons, and in LEMS, 3,4-DAP facilitates the transmission at the neuromuscular endplate by prolonging the action potential duration. SUMMARY: There is sufficient evidence that APs are indicated for the symptomatic treatment of DBN, EA2, gait ataxia due to MS and cerebellar disorders, and LEMS with a reasonable risk-benefit profile.
PURPOSE OF REVIEW: To identify the different indications for the treatment of neurologic disorders with the potassium channel blockers 4-aminopyridine (4-AP) and 3,4-diaminopyridine (3,4-DAP). RECENT FINDINGS:4-AP is an effective symptomatic treatment for downbeat nystagmus (DBN), episodic ataxia type 2 (EA2) (5-10 mg TID), and impaired gait in multiple sclerosis (MS) (10 mg BID). 3,4-DAP (5 mg/d-20 mg TID) improves symptoms in Lambert-Eaton myasthenic syndrome (LEMS) (randomized placebo-controlled trials for all 4 entities). 4-AP may also be effective in cerebellar gait ataxia of different etiologies (2 case series), upbeat nystagmus, and limb ataxia in MS (single cases). In the recommended dosages, they are well tolerated. The assumed mode of action is a blockade of mainly Kv1.5: in DBN, this increases the excitability of Purkinje cells (PC), and in EA2, restores the precision of resting discharge of PC. In MS, 4-AP improves the conduction of action potentials in demyelinated axons, and in LEMS, 3,4-DAP facilitates the transmission at the neuromuscular endplate by prolonging the action potential duration. SUMMARY: There is sufficient evidence that APs are indicated for the symptomatic treatment of DBN, EA2, gait ataxia due to MS and cerebellar disorders, and LEMS with a reasonable risk-benefit profile.
Authors: Roger Kalla; Rainer Spiegel; Jens Claassen; Stanislavs Bardins; Ales Hahn; Erich Schneider; Nicole Rettinger; Stefan Glasauer; Thomas Brandt; Michael Strupp Journal: J Neuroophthalmol Date: 2011-12 Impact factor: 3.042
Authors: A D Goodman; J A Cohen; A Cross; T Vollmer; M Rizzo; R Cohen; L Marinucci; A R Blight Journal: Mult Scler Date: 2007-01-29 Impact factor: 6.312
Authors: Michael Strupp; Julia Dlugaiczyk; Birgit Bettina Ertl-Wagner; Dan Rujescu; Martin Westhofen; Marianne Dieterich Journal: Dtsch Arztebl Int Date: 2020-04-24 Impact factor: 5.594
Authors: Kristine S Ojala; Scott P Ginebaugh; Man Wu; Evan W Miller; Gloria Ortiz; Manuel Covarrubias; Stephen D Meriney Journal: J Biol Chem Date: 2021-01-17 Impact factor: 5.157
Authors: Michael Strupp; Stephan Maul; Bettina Konte; Annette M Hartmann; Ina Giegling; Sophia Wollenteit; Katharina Feil; Dan Rujescu Journal: Cerebellum Date: 2020-06 Impact factor: 3.847
Authors: J Marsden; M Pavlou; R Dennett; A Gibbon; R Knight-Lozano; L Jeu; C Flavell; J Freeman; D E Bamiou; C Harris; A Hawton; E Goodwin; B Jones; S Creanor Journal: BMC Neurol Date: 2020-11-27 Impact factor: 2.474